Condition: Multiple Sclerosis · Clinically Isolated Syndrome of Demyelination · Sponsor: Queen Mary University of London
Multiple Sclerosis (MS) is a chronic inflammatory \& degenerative disease of the central nervous system (CNS) Recent data from the MS Base registry demonstrated an average delay of 152 - 215 days between first presentation and the diagnosis of MS, and more than one year until Disease Modifying Treatment (DMT) begins. Evidence suggests that shutting down inflammation using highly effective DMTs early after diagnosis leads to better long term clinical outcomes The AttackMS trial will test the effect of starting a highly-effective DMT licensed for MS, Tyruko® (Natalizumab 300mg), within a short time - 14 days - after symptom onset.
This description comes directly from the study's public registry record.
Klaus Schmierer · +44 20 7882 6246 · k.schmierer@qmul.ac.uk
Julia Elizabeth Phillips · attackms@qmul.ac.uk
Always discuss trial participation with your own doctor first.
| Royal London Hospital | London, United Kingdom | Not Yet Recruiting |
| St George's Hospital | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05418010